ABBV Abbvie Inc

$ABBV $VKTX $ABBV headline data today on GUBRA amylin presentation. Someone probably will provide slides. But no details on all AEs and 4.4% placebo adjusted DC due to GI AE is not good for an amylin. It’s higher than what reported with leading incretins $LLY TZP and $VKTX 2735 Half life 10-12 days is C/W with what available out there from other mechanisms as CEO continues to mull combination ( which doesn’t seem to be a good idea with this amylin based on above )

Just like yesterday, the stocks making new 52-week relative strength high vs the S&P 500 are defensive healthcare and consumer staples stocks like $ABBV $BIIB $KO etc.

$ABBV Regardless if we are in a recession or not people are always going to get sick and medicine is going to be needed around the world 🌏🌎🌍 we are still early with $ABBV

$ABBV $KURA $SNDX This is a hematologist prescriber survey embedded within the recent SNDX note, focused on NPM1 mutant AML (the largest subset of adult AML, ~30% of all AML). Core survey findings 1. Diagnosis & testing behavior Virtually all responding leukemia specialists now routinely test newly diagnosed AML patients for NPM1 mutation at baseline. Previously, many viewed revumenib only as a KMT2Ar drug; survey shows this perception has shifted after NPM1 label approval + real-world data. 2. Treatment preference for R/R NPM1 AML (already approved setting) ◦ Efficacy / deep MRD response is the #1 decision factor (ranked far above safety, oral convenience, or price). ◦ HCPs say revumenib’s ability to drive MRD negativity is its biggest differentiator vs older salvage regimens. ◦ Survey uptake expectation: Respondents expect Revuforj to capture a dominant share of eligible R/R NPM1 patients, even with competing menin inhibitor now on market.

$ABBV FDA approved subcutaneous induction for SKYRIZI in Crohn's disease on Friday, so patients can now start at home with the on-body injector instead of an infusion center. Same device carries them through maintenance every 8 weeks. In the Phase 3 AFFIRM study, 56% hit clinical remission at week 12 vs 30% on placebo, and endoscopic response was 43% vs 15%. Among patients new to advanced therapy it was 74% vs 27%, and 65% of the study population had already failed an advanced therapy.

$ABBV AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease

$ABBV 🏥 The U.S. FDA approved a subcutaneous induction regimen for AbbVie's SKYRIZI (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease, expanding administration options with an on-body injector.

$ABBV Mrch 320c, good entry point, but be sure to know ER is coming so dont go heavy, ER can do what it did to $JNJ and then pump again

The Nasdaq dropped 1.9% yesterday. $ABBV closed at a record high. This morning it pushed through 285.40, tagging 290.56. Now the job is holding above 285.40 into the close. That's what I'm watching.

$ABBV I’ve just stubbornly held this since the spin out in 2013 collecting dividends and capital appreciation the entire way instead of trying to trade it like the day flippers and hedge funds. A good lesson for the kids out there!

$ABBV I at least added this yesterday, 274.94 ath. But made more mistakes yesterday than any day the last three months. So many false breakouts.

$ABBV What a monster stock this has been ... now consolidating over the base for potential next leg up

$ABBV NOV20 300C · still actionable Zone: $285.40 to $289.40 Invalidation: close under $282.15 Objectives: $291.40, then $300 The math: up 1.4% to the first objective and 4.4% to the second, against 1.8% risk on the invalidation, better than 2 to 1 to the second. Dear friend, think of a runner who was already close to the front and then got good news at breakfast. AbbVie closed at 284.80 dollars on Wednesday and was trading near 287.40 dollars before the bell today after its lutikizumab study met its main goal in Phase 3, and that matters because buyers now have a fresh reason to press price toward the 291.40 dollar high with earnings on October 30 still ahead. This is a swing setup built on strength holding above the 282.15 dollar low from Wednesday, where sellers tried and failed to push it lower. P.S. Watch the 291.40 dollar high today, friend. A close above it would put the round 300 dollar line in plain sight.

$ABBV 🏥 AbbVie Inc. announced topline results from the Phase 3 INTREPID trial showing lutikizumab significantly improved signs and symptoms in patients with hidradenitis suppurativa. Actionable market event

$ABBV: AbbVie's own premarket testing is in the Juvederm complaint: 65% to 68% of subjects allegedly had lumps and bumps, 11% to 22% nodules. Plaintiffs allege granuloma risk still went unwarned. Nothing to claim. Open Class Actions.

$ABBV AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio "New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine"

$ABBV: the Juvederm suit cites a 2022 study putting delayed nodules at 0.5% to 0.98% for the filler family, higher than rivals. It alleges AbbVie never warned of granulomas. No class certified, nothing to claim. Open Class Actions.

$ABBV $AAPL Market seems to rotating from the fraud AI complex into real companies like ABBV and AAPL.

$ABBV $MRK $PFE I normally avoid posting on my big pharma holding boards because they are small cap bio pump sesspools, but nice day!!

$ABBV (AbbVie) gets FDA approval for tavapadon (brand name Juvmo), a once-daily pill for Parkinson's disease, with the drug acquired through AbbVie's 2023 purchase of Cerevel Therapeutics.